Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.
Transcript:
What benefits do biosimilars offer to providers and to the healthcare system?
Biologic drugs have really revolutionized the practice [and] treatment of rheumatoid arthritis, and other autoimmune diseases, but that has come at a tremendous cost and oftentimes the price is a lack of access to drugs. So, it’s one of the things that gets me up out of bed in the morning, and what I really like my job for, is that I can see people, and diagnose them, and put a treatment plan in place that’s going to get them back to work and reduce their aching joints. But, it’s heartbreaking when people can’t get access to the drugs because they’re too expensive. The best thing that biosimilars give to providers, and also to patients, is the promise of increased access to care, so that everybody who needs one of these drugs can get on it, afford it, and have it also be affordable for society at large—that’s the benefit of biosimilars. In short, that’s the benefit of biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.